Works matching IS 03331024 AND DT 2022 AND VI 42 AND IP 8
Results: 16
Board Walk – July 2022.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 810, doi. 10.1177/03331024221096337
- By:
- Publication type:
- Article
Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 781, doi. 10.1177/03331024221077665
- By:
- Publication type:
- Article
Unilateral increased visual sensitivity in cluster headache: a cross-sectional study.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 722, doi. 10.1177/03331024221077664
- By:
- Publication type:
- Article
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 696, doi. 10.1177/03331024221077646
- By:
- Publication type:
- Article
Corrigendum to: PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 769, doi. 10.1177/03331024221076485
- By:
- Publication type:
- Article
Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 730, doi. 10.1177/03331024221076484
- By:
- Publication type:
- Article
The spectrum of indomethacin-responsive headaches in children and adolescents.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 793, doi. 10.1177/03331024221076483
- By:
- Publication type:
- Article
Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 705, doi. 10.1177/03331024221076481
- By:
- Publication type:
- Article
The clinical characteristics of familial cluster headache.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 715, doi. 10.1177/03331024221076478
- By:
- Publication type:
- Article
Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 749, doi. 10.1177/03331024221075621
- By:
- Publication type:
- Article
Interictal plasma endothelin-1 levels do not change in individuals with episodic and chronic migraine.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 761, doi. 10.1177/03331024221075616
- By:
- Publication type:
- Article
Effects of cluster headache preventatives on mouse hypothalamic transcriptional homeostasis.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 798, doi. 10.1177/03331024221075613
- By:
- Publication type:
- Article
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 804, doi. 10.1177/03331024211068074
- By:
- Publication type:
- Article
PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 687, doi. 10.1177/03331024211056248
- By:
- Publication type:
- Article
Facial expressions modulate pain perception in patients with chronic migraine.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 739, doi. 10.1177/03331024221075081
- By:
- Publication type:
- Article